ADMA Biologics: RSI Oversold and KDJ Golden Cross on 15-Minute Chart

ADMA Biologics's 15-minute chart has exhibited several significant technical indicators. Specifically, the Relative Strength Index (RSI) has entered an oversold state, and the KDJ indicator has recently formed a golden cross at 09:29:2025 14:15. These signals collectively suggest that the stock price has dropped precipitously and has fallen below its fundamental support level, indicating a shift in momentum towards an upward trajectory with potential for further appreciation.

Adma Biologics (ADMA) closed the most recent trading day at $15.32, down by 2.17% from the previous session, lagging the S&P 500's daily loss of 0.5%. This decline comes after a significant drop of 9.22% over the past month, which was slower than the Medical sector's loss of 0.7% and the S&P 500's gain of 2.74% Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

Analysts and investors are closely watching Adma Biologics as the company is expected to post earnings per share (EPS) of $0.16 for the quarter, indicating a 6.67% growth compared to the same period last year. The consensus estimate also projects quarterly revenue of $130.1 million, up 8.56% year-over-year Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

Looking ahead, the full-year Zacks Consensus Estimates predict earnings of $0.57 per share and revenue of $506.7 million, representing year-over-year changes of +16.33% and +18.82%, respectively Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1]. Despite these positive estimates, the stock has been under pressure, with recent changes in analyst estimates indicating a shift in near-term business trends.

Technically, the 15-minute chart of ADMA Biologics exhibits several significant indicators. The Relative Strength Index (RSI) has entered an oversold state, suggesting that the stock price may be undervalued. Additionally, the KDJ indicator has recently formed a golden cross at 09:29:2025 14:15, indicating a shift in momentum towards an upward trajectory .

The current Forward P/E ratio of 27.47 for ADMA Biologics denotes a premium relative to the industry average Forward P/E of 19.43. The Medical - Biomedical and Genetics industry, which includes ADMA Biologics, has a Zacks Industry Rank of 88, placing it in the top 36% of all 250+ industries Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].

Investors should monitor these technical indicators and valuation metrics closely, as they can provide valuable insights into the stock's potential for further appreciation. The Zacks Rank system, which considers estimate changes and provides a simple rating system from #1 (Strong Buy) to #5 (Strong Sell), currently rates ADMA Biologics as a #3 (Hold) Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors^[1].